NEW YORK--(BUSINESS WIRE)--Massive Bio, a Manhattan-based startup, providing personalized advisory services for cancer patients, oncologists and oncology practices will begin offering its on-demand services publicly on June 1, following rigorous testing over the past three months.
The service is designed to support oncologists in community-based practices, i.e. non-academic centers, whose cumulative caseload represents the majority of cancer patients in the United States. Such oncologists often lack access to in-house resources like cancer genomics tests, or other advanced tumor-profiling technologies, readily available to their peers in major academic centers, said Selin Kurnaz, the company's co-founder and CEO. Even if they do order such tests, bringing the information to bear on their patients' care and convincing insurance companies to cover the treatments remain tremendous challenges, she added.
With a team ranging from specialty oncologists to cancer-genomics and computer scientists, and even reimbursement experts, Massive Bio can assist with complex cancers and difficult cases with comorbidities; provide assistance with cancer genomics test selection and treatment options when standard approaches like chemotherapy have failed, leading to an overall improvement in quality of care while minimizing costs.
While providing a trial version of its services, the company was often able to uncover promising new treatments being tested at hospitals near patients, or recently approved treatments that offered a better survival rate or fewer side-effects, said Cyriac Kandoth, Massive Bio’s chief technologist. For promising treatments that don’t yet have regulatory approval, Massive Bio gathers evidence that can help with obtaining reimbursement for off-indication use, or alternatively assists in clinical trial selection.
Massive Bio delivers its findings to primary oncologists of cancer patients within an average of 3 to 5 days, at an affordable price to patients. Success-based pricing correlated with a reduction in co-payment amounts is coming shortly for cancer patients, and select international coverage will also be provided. Orders can be made through the company’s website (https://massbio.io/order) or via e-mail (email@example.com) by cancer patients or their primary oncologists.
In addition to single case on-demand advisory, Massive Bio will offer an enterprise wide solution on a subscription basis, which is integrated with oncology practice’s Electronic Health Record (EHR) system, and allows the advisory services to be used at a large scale in an automated way starting early Q3 2015. However, oncology practices are welcome to order on-demand advisory services in the meantime.
Massive Bio’s senior management team will be introducing their services starting May 29 at the American Society of Clinical Oncology (ASCO)’s annual meeting in Chicago. You can still schedule interviews with the team by making an appointment for demonstration from the following link https://calendly.com/massbio/asco or sending an email to firstname.lastname@example.org.
About Massive Bio: Massive Bio is a Manhattan-based start-up that brings next-generation testing and treatment recommendations to community oncologists using academic expertise in cancer genomics. Massive Bio's Personalized Oncology Advisor (MB-POA) helps oncologists and oncology practices around the globe to incorporate cancer genomics, targeted therapies, and outcomes-tracking into their daily decisions. Our product is available on-demand per-case, or as an enterprise solution integrated with an oncology practice's Electronic Health Record (EHR) provider. We are the only company in the market that provides both clinical and economic benefits, from vendor-agnostic interpretation of cancer genomics to reimbursement support, and personalizes available options for cancer patients.